Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab. J of Skin. 2017;1(3.1):s5. doi:10.25251/skin.1.supp.4